Journal of controlled release : official journal of the Controlled Release Society

J Control Release · ISSN (e) 1873-4995 · 14 papers in corpus
article 2026
doi:10.1016/j.jconrel.2026.115007 ·PMID:42114779

Fibroblast growth factor receptor 2 (FGFR2) has emerged as a highly promising therapeutic target due to its critical role in the pathogenesis and progression of endometriosis. To date, a variety of FGFR2 inhibitors have exhibited remarkable…

2025
doi:10.1016/j.jconrel.2025.01.075 ·PMID:39894266

Biofilms increase bacterial resistance to antibiotics, as conventional antibiotic doses are often ineffective at penetrating the biofilm matrix to eliminate bacteria. Recent research has shown that the Gram-negative predator bacterium Bdell…

2025
doi:10.1016/j.jconrel.2025.114028 ·PMID:40683601

Drug delivery systems (DDS) enhance drug delivery for treating gynecological cancers by increasing the bioavailability of commonly prescribed chemotherapeutics in these cancers. Gynecological cancers may originate in the ovary or fallopian …

other 2025
doi:10.1016/j.jconrel.2024.12.074 ·PMID:39742921

Endometriosis, the growth of endometrial-like tissue outside the uterus, causes chronic pain and infertility in 10 % of reproductive-aged women worldwide. Unfortunately, no permanent cure exists, and current medical and surgical treatments …

2025
doi:10.1016/j.jconrel.2024.11.022 ·PMID:39542256

Severe acute pancreatitis (SAP) is an inflammatory disease of the pancreas accompanied with intestinal injury, and effective therapeutic modalities are still highly lacking. Herein, a facile and effective nanotherapeutics (pHA@IBNCs) is dev…

review 2024
doi:10.1016/j.jconrel.2023.07.016 ·PMID:37544514

My contribution to honoring Professor Kinam Park celebrates and resonates with his scholarly career in drug delivery, his commitment to encouraging the next generation(s), and his efforts to keep us focused on clinically effective formulati…

review 2024
doi:10.1016/j.jconrel.2024.10.036 ·PMID:39427778

Endometriosis, defined by the growth of endometrial tissues outside of the uterine cavity, is a global health burden for ∼200 million women. Patients with endometriosis usually present with chronic pain and are often diagnosed with infertil…

2016
doi:10.1016/j.jconrel.2016.09.023 ·PMID:27664328

Nitrogen-containing bisphosphonates (N-BP), including zoledronic acid (ZOL) and alendronate (ALD), have been proposed as sensitisers in γδ T cell immunotherapy in pre-clinical and clinical studies. Therapeutic efficacy of N-BPs is hampered …

2015
doi:10.1016/j.jconrel.2015.08.018 ·PMID:26278511

Efflux and uptake transporters of drugs are key regulators of the pharmacokinetics of many antiretroviral drugs. A growing body of literature has revealed the expression and functionality of multiple transporters in female genital tract (FG…

2014
doi:10.1016/j.jconrel.2014.03.053 ·PMID:24747160

Drug delivery systems are widely researched and developed to improve the delivery of pharmaceutical compounds and molecules. The last few decades have seen a marked growth of the field fueled by increased number of researchers, research fun…

2014
doi:10.1016/j.jconrel.2014.04.049 ·PMID:24798478

Drug design is built on the concept that key molecular targets of disease are isolated in the diseased tissue. Systemic drug administration would be sufficient for targeting in such a case. It is, however, common for enzymes or receptors th…

2013
doi:10.1016/j.jconrel.2013.08.295 ·PMID:24021356

An important poorly understood phenomenon in controlled-release depots involves the strong interaction between common cationic peptides and low Mw free acid end-group poly(lactic-co-glycolic acids) (PLGAs) used to achieve continuous peptide…

article 2010
doi:10.1016/j.jconrel.2010.08.030 ·PMID:20813142

Innate immunity and inflammation are of major importance in various pathological conditions. Intravenous (IV) and intraperitoneal (IP) liposomal alendronate (LA) treatments have been shown to deplete circulating monocytes and peritoneal mac…

other 2005
doi:10.1016/j.jconrel.2005.08.016 ·PMID:16182402

The recent advent of biotechnologies has led to the development of labile macromolecular therapeutic agents that require complex formulations for their efficient administration. This work reports a novel concept for the systemic, sustained …